These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36942869)

  • 1. Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action.
    Roglans N; Laguna JC; Alegret M
    Curr Opin Lipidol; 2023 Aug; 34(4):141-146. PubMed ID: 36942869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid.
    Velázquez AM; Bentanachs R; Sala-Vila A; Lázaro I; Rodríguez-Morató J; Sánchez RM; Laguna JC; Roglans N; Alegret M
    Biomedicines; 2022 Jun; 10(7):. PubMed ID: 35884822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
    Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
    Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model.
    Bentanachs R; Velázquez AM; Sánchez RM; Alegret M; Laguna JC; Roglans N
    Clin Investig Arterioscler; 2022; 34(2):57-67. PubMed ID: 34887111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice.
    Desjardins EM; Wu J; Lavoie DCT; Ahmadi E; Townsend LK; Morrow MR; Wang D; Tsakiridis EE; Batchuluun B; Fayyazi R; Kwiecien JM; Tsakiridis T; Lally JSV; Paré G; Pinkosky SL; Steinberg GR
    Cell Rep Med; 2023 Sep; 4(9):101193. PubMed ID: 37729871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
    Guo L; Guo YY; Li BY; Peng WQ; Chang XX; Gao X; Tang QQ
    J Biol Chem; 2019 Aug; 294(31):11805-11816. PubMed ID: 31197036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score.
    Sanjay KV; Vishwakarma S; Zope BR; Mane VS; Mohire S; Dhakshinamoorthy S
    Curr Res Pharmacol Drug Discov; 2021; 2():100051. PubMed ID: 34909677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (
    Burke AC; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Barrett PHR; Newton RS; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1178-1190. PubMed ID: 29449335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic Acid Restores Liver H
    Roglans N; Fauste E; Bentanachs R; Velázquez AM; Pérez-Armas M; Donis C; Panadero MI; Alegret M; Otero P; Bocos C; Laguna JC
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Role of Bempedoic Acid in Metabolic Dysfunction Associated Steatotic Liver Disease: Actual Evidence and Future Perspectives.
    Butera E; Termite F; Esposto G; Galasso L; Mignini I; Borriello R; Ainora ME; Miele L; Gasbarrini A; Zocco MA
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
    Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice.
    Li K; Zhang K; Wang H; Wu Y; Chen N; Chen J; Qiu C; Cai P; Li M; Liang X; Su D
    Metabolism; 2021 Jan; 114():154349. PubMed ID: 32888949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
    Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
    J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD.
    Sun Q; Niu Q; Guo Y; Zhuang Y; Li X; Liu J; Li N; Li Z; Huang F; Qiu Z
    J Agric Food Chem; 2021 Aug; 69(31):8714-8725. PubMed ID: 34323067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.
    Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS
    J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATP Citrate Lyase and LncRNA NONMMUT010685 Play Crucial Role in Nonalcoholic Fatty Liver Disease Based on Analysis of Microarray Data.
    Ma TT; Huang C; Ni Y; Yang Y; Li J
    Cell Physiol Biochem; 2018; 51(2):871-885. PubMed ID: 30466110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.